AUTHOR=Wang Yuan , He Jing , Xu Manyu , Xue Qingfeng , Zhu Cindy , Liu Juan , Zhang Yaping , Shi Wenyu 

TITLE=Holistic View of ALK TKI Resistance in ALK-Positive Anaplastic Large Cell Lymphoma

JOURNAL=Frontiers in Oncology

VOLUME=Volume 12 - 2022

YEAR=2022

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.815654

DOI=10.3389/fonc.2022.815654

ISSN=2234-943X

ABSTRACT=Anaplastic large cell lymphoma kinase (ALK) is a receptor tyrosine kinase (RTK), which is mainly expressed through the ectopic expression of carcinogenesis. It plays a key role in the occurrence of Anaplastic lymphoma kinase-expressing T-cell lymphoma (ALK+ ALCL). Therefore, it is considered to be the main therapeutic target of ALK+ ALCL. The application of ALK-TKI (ALK Tyrosine Kinase Inhibitor) has greatly improved the therapeutic effect of ALK+ALCL patients, but the emergence of drug resistance is still unavoidable and the application of ALK inhibitors is also greatly restricted. Although various mechanisms of ALK-TKI resistance have been discovered, the problem of resistance has not been completely solved. More importantly, there are relatively few clinical studies of AlK-TKI resistance . Therefore, this review focuses on the research progress of ALK+ALCL, including the application and development of new therapeutic technologies, especially in terms of drug resistance. Meanwhile, we propose potential treatment strategies based on current research to facilitate clinical trials.